Hadjadj and colleagues [11] demonstrated that IFN-I signaling was highly dysregulated in severely or critically ill COVID-19 patients, as indicated by low IFN-I and ISGs levels, despite increased levels of TNF-, IL-6-, and NF-κB-driven inflammatory responses. The gene discussed is IL6; the disease is COVID-19.